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Abstract 
 
Extracellular signal-regulated kinases (ERK) have fundamental roles in tumor progression. 
However, human clinical trials have shown little or no effect of inhibitors of their upstream 
signaling molecule, mitogen-activated protein kinase/ERK kinase (MEK), in advanced cancers. 
To determine the molecular mechanism underlying the limited antitumor effect, we cultured 
two human renal carcinoma cell lines, ACHN cells and VMRC-RCW cells in the presence of a 
MEK inhibitor PD98059 for more than 4 weeks (PD98059-exposed cells). PD98059-exposed 
ACHN cells showed elongated cell shape with scattering morphology, increase in vimentin 
expression, loss of -catenin junctional localization, stress fiber formation, and increased 
motility. In contrast, VMRC-RCW cells showed scattered phenotype without 
PD98059-treatment and this treatment failed to increase the expression of vimentin. Rho A 
activity was increased in PD98059-exposed ACHN cells. In these cells, enhanced stress fiber 
formation and motility were observed, both of which were inhibited by treatment with small 
interfering RNA for Rho A or a Rho kinase inhibitor Y27632. Our results suggest that 
long-term exposure of human renal carcinoma cells to PD98059 increases cell motility by 
upregulating Rho A-Rho kinase signaling.  
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Introduction 
 
Extracellular signal-regulated kinases (ERK) 1 and 2, activated by mitogen-activated protein 
kinase (MAPK)/ERK kinase (MEK), play essential roles in tumor progression and 
angiogenesis [1, 2]. In particular, activated ERK contributes to tumor cell motility [3]. MEK 1 
and 2 are the only upstream molecules that can activate ERK; thus, inhibition of MEK 
exclusively attenuates ERK activity [4]. In human cancer cells, ERK is more highly activated 
than it is in normal adjunct cells [5]. However, clinical trials have shown that the use of MEK 
inhibitors as a treatment for advanced cancer do not adequately improve survival [6, 7]. The 
reason for the poor outcome of MEK inhibitor therapy in patients with cancer is not clear. The 
low sensitivity of malignant cells to MEK inhibitors was noted in two previous studies to be 
due to upregulation of K-Ras or mutation of B-Raf [8, 9]. In addition, we found that long-term 
exposure of human renal carcinoma cells (ACHN cells) and hormone-refractory prostate 
cancer cells (DU145 cells) to PD98059, a MEK inhibitor, reduced their proliferation sensitivity 
to PD98059 by upregulation of ERK2 protein [10]. Interestingly, we observed in that study 
[10] that PD98059-treated ACHN cells exhibited an elongated and fibroblastic morphology 
with scattered phenotype. These morphological changes are frequently observed in 
epithelial-mesenchymal transition (EMT), a process involved in tumor cell invasion and 
metastasis [11, 12].  
The present study was designed to explore the molecular mechanisms underlying 
EMT-like changes and associated cellular responses in ACHN cells during long-term exposure 
to PD98059. 
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Anti–pan-cytokeratin monoclonal antibody (C11), anti-Rho A monoclonal antibody (26C4), 
anti-E-cadherin (G-10), anti--catenin (H-102), and non-targeting control small interfering 
RNA (siRNA) were purchased from Santa Cruz Biotechnologies (Santa Cruz, CA). 
Hs_RHOA_6 and _7 HP Validated siRNA, and HiPerFect transfection reagent were obtained 
from QIAGEN. K. K. (Tokyo, Japan). Anti-vimentin monoclonal antibody (V9) was 
purchased from Chemicon International (Temecula, CA). Anti-human vinculin monoclonal 
antibody, TRITC-conjugated phalloidin, minimal essential medium (MEM), and non-essential 
amino acids (NEAA) were purchased from Sigma Chemical Company (St. Louis, MO). 
Rhotekin Rho binding domain (RBD)-glutathione S-transferase (GST) fusion protein coupled 
to agarose beads was obtained from Upstate Cell Signaling Solutions (Temecula, CA). Fetal 
bovine serum (FBS) was obtained from Invitrogen Corporation (Carlsbad, CA). Y27632 was 
obtained from Merck Bioscience (Calbiochem, La Jolla, CA). PD98059 (Wako Pure 
Chemicals, Osaka, Japan) was dissolved in dimethyl sulfoxide (DMSO) and stored at -80°C 
until use. After thawing, it was dissolved in the culture medium and added to the cells. The 




Human renal carcinoma cell lines, ACHN cells and VMRC-RCW cells [13], were cultured in 
MEM supplemented with NEAA and 10% FBS. For long-term exposure of cells to PD98059, 
the cells were continuously cultured in the presence of 50 µM PD98059 for more than 4 weeks. 
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Unexposed parental cells were designated as ACHNpa and VMRC-RCWpa cells, respectively, 
and cells chronically exposed to PD98059 were designated as ACHNPD cells and 




Cells were grown in 24-well plates. Two sets of cultures were prepared: one set was used for 
immunoblotting and the other set was used for cell counts. The culture medium for cells 
chronically treated with PD98059 was always supplemented with 50 µM PD98059. Cells were 
lysed by boiled SDS-sample buffer, and the proteins from equal number of cells in each lysate 
were separated on SDS polyacrylamide gels. Proteins were electrotransferred onto 
polyvinylidene difluoride (PVDF) membranes (Millipore, Bedford, MA). Membranes were 
incubated with the indicated antibodies, followed by incubation with peroxidase-conjugated 
secondary antibodies. Proteins were visualized using enhanced chemiluminescence reagents 
(Pierce Biotechnology, Rockford, IL) and exposed on X-ray films. The membranes were 
stripped between two probings, as described previously [14]. 
 
Indirect immunofluorescent staining 
 
Indirect immunofluorescent staining was performed as described previously [15]. Cells were 
seeded onto the surface of coverslips with or without PD98059 and cultured for2 days. Cells 
were washed with PBS, fixed with 3.7% paraformaldehyde, and permeabilized with 0.05% 
Triton X-100. After the blocking of nonspecific protein binding with PBS supplemented with 
5% dry milk and 10% goat serum, cells were stained with anti-E-cadherin monoclonal 
antibody or anti--catenin polyclonal antibody. Primary antibodies were visualized with 
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corresponding secondary antibodies labeled with biotin, followed by the incubation with 
streptoavidin-Alexa Fluor 555 conjugates. 
 
Examination of stress fiber formation 
 
Stress fiber formation was determined as described previously [13]. In brief, cells (2  104 
cells/well) were seeded onto cover slips in 24-well plates and cultured for 20 h. They were then 
incubated in a serum-free medium for 3 h and either stimulated with 10% FBS for 20 min or 
left unstimulated. Cells were then fixed with 3.7% paraformaldehyde in phosphate-buffered 
saline (PBS) for 20 min at room temperature, followed by incubation with 0.1% Triton X-100 
in Tris-buffered saline (TBS) for 3 min. Cells were washed with TBS and incubated with 
TRITC-conjugated phalloidin for 20 min. After washing and mounting, photographs were 




To quantify cell migration, we performed the chemokinesis assays [13]. Briefly, cells were 
suspended in a serum-free medium and placed onto the upper surface of the membranes of 
Transwell inserts (6.7-mm in diameter, 8-µm pore) pre-coated with bovine type I collagen (30 
mg/ml) at a density of 1.5  104 cells/membrane. The inserts were then placed in wells 
containing serum-free medium with or without 10% FBS. The culture medium of cells treated 
with PD98059 for more than 4 weeks was always supplemented with 50 µM PD98059. The 
cells were incubated for 24 h and fixed with 100% methanol. Cells on the upper surface were 
removed by cotton swabs, while those that migrated to the surface of the lower membrane of 
the Transwell inserts were stained with Giemza solution and counted microscopically.  
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Assay for Rho A activity 
 
The GTP-bound active form Rho A was precipitated from the indicated cell lysate with 
Rhotekin RBD-GST conjugated beads using the protocol provided by the manufacturer. 
ACHNpa cells or ACHNPD cells were cultured in the presence of 10% FBS and lysed in the 
Mg2+ lysis buffer [25 mM N-2-hydroxyetylpiperazine-N’-ethanesulphonic acid (HEPES), pH 
7.5, 150 mM NaCl, 1% Igepal CA-630, 10 mM MgCl2, 1 mM ethylenediaminetetraacetic acid 
(EDTA), and 2% glycerol]. Ninety percent of lysate was incubated with Rhotekin RBD-GST 
conjugated beads and bound proteins were separated on SDS-polyacrylamide gels, followed by 
transfer onto polyvinylidene fluoride (PVDF) membranes (Millipore, Bedford, MA). Rho A 
protein was detected by immunoblotting as described above. The remaining 10% lysate was 
examined for the loaded amount of proteins.  
 
Treatment of cells with siRNA 
 
Treatment of cells with siRNA (25 nM each) was described previously [10]. Briefly, ACHNPD 
cells were cultured in wells of 24-well plates. The culture medium was replaced with a fresh 
medium containing 10% FBS. A serum-free medium supplemented with HiPerFect reagent 
and control siRNA, or either Hs_RHOA_6 or _7 HP Validated siRNA at 25 nM, was added to 
the cells. After 2 days, the cells were detached and their number counted. A portion of the 
suspended cells was used for chemokinesis assay and the remaining cells were examined for 
the expression of Rho A proteins by immunoblotting as described above. 
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Statistical analysis 
 
Values are presented as mean cell numbers ± SD. Differences between two groups were 
analyzed using the Mann-Whitney U test. Differences were considered significant when P < 
0.05. 
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Results 
 
Long-term exposure to PD98059 induces EMT-like phenotype of ACHN cells 
 
ACHN cells grow as a compact seat with cell-cell contact, whereas VMRC-RCW cells grow 
without cell-cell contact (scattered morphology) [13]. We first examined the effect of 
short-term PD98059 treatment on serum-activated ERK in these cells. As shown in Fig. 1, 
serum-treatment activated ERK in these cells with similar kinetics and treatment with 
PD98059 strongly inhibited the activation. This result suggests that PD98059 used in this study 
is active against ERK activation. We then cultured these cells in the presence or absence of 50 
M of PD98059 for more than 4 weeks. As shown in Fig. 2A, ACHNPD cells showed an 
elongated cell shape with scattered morphology, whereas long-term exposure to PD98059 did 
not induce any morphological changes in VMRC-RCWPD cells (Fig. 2C). Next, we prepared 
total cell extracts and determined the expression of cytokeratin (a marker of epithelial cells) 
and vimentin (a marker of mesenchymal cells). As shown in Fig. 2B, expression of cytokeratin 
was not altered in ACHNPD cells. In contrast, expression of vimentin was increased in these 
cells. In VMRC-RCW cells, no such alteration was observed (Fig. 2D). Long-term treatment of 
ACHN cells with PD98059 reduced their growth sensitivity to PD98059 treatment through 
upregulation of ERK 2 (10). Upregulation of ERK was observed in both ACHNPD cells and 
VMRC-RCWPD cells (Fig. 2D) and the decrease in growth sensitivity to PD98059 was also 
observed in these cells (data not shown). We also examined the expression of E-cadherin 
and-catenin in these cells assessed by immunoblotting. However, no alteration of the 
expression of these proteins was observed (data not shown). Because the expression of 
E-cadherin in these cells was relatively low, we investigated the localization of -catenin in 
ACHN cells. As shown in Fig. 2 E, -catenin was localized at the site of cell-cell contact 
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(junctional localization). Chronic exposure to PD98059 disrupted the junctional localization of 
-catenin. These results suggest that long-term exposure of ACHN cells to PD98059 induces 
EMT-like phenotype. This phenotype was reversible because culture of ACHNPD cells in the 
absence of PD98059 for 2 weeks reverted the morphological changes as well as expression of 
vimentin (data not shown).  
 
The EMT-like phenotype of ACHNPD cells is associated with enhanced cell motility 
 
EMT is involved in metastatic progression of tumor cells partly by enhanced cell motility [11, 
12]. We examined stress fiber formation in ACHNpa and (PD) cells. As shown in Fig. 3A, 
FBS-treatment induced stress fiber formation in ACHNpa cells. In contrast, ACHNPD cells 
showed enhanced stress fiber formation in the absence of FBS. FBS-treatment induced 
lamellipodia formation in these cells. We also examined the random motility of these cells by 
the chemokinesis assay. As shown in Fig. 3B, chemokinesis of ACHNpa cells was stimulated 
by treatment with FBS. Chemokinesis of ACHNPD cells was significantly higher than that of 
ACHNpa cells in the absence of FBS and FBS did not further stimulate cell migration. These 
results suggest that the EMT-like phenotype of ACHNPD cells is associated with enhanced cell 
motility, which may increase their metastatic potential in vivo. 
 
Elevated Rho A activity may be responsible for PD98059-induced EMT in ACHN cells 
 
Previous studies showed that inhibition of ERK pathway in cancer cells resulted in 
upregulation of Rho-Rho kinase signaling [16, 17]. There is also evidence for the involvement 
of Rho signaling in EMT [11, 12]. Rho A regulates stress fiber formation, whereas Rac and 
Cdc42 regulate lamellipodia and filopodia, respectively [18, 19]. We first examined the 
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activity of Rho A in ACHNpa and ACHNPD cells. As shown in Fig. 4A, increased binding of 
active Rho A to RBD-GST fusion protein was observed in ACHNPD cells compared with 
parental cells. Rac and Cdc42 activities were not upregulated in ACHNPD cells (data not 
shown). The difference of Rho A activity between VMRC-RCWpa cells and VMRC-RCWPD 
cells was not observed (data not shown). FBS-treatment increased activated Rho A in ACHNpa 
cells, but not in ACHNPD cells (data not shown). These observations were compatible with the 
enhanced stress formation without lamellipodia and filopodia observed in ACHNPD cells. We 
next examined the effect of downregulation of endogenous Rho A by siRNA on ACHNPD cells. 
As shown in Fig. 4B, Hs_RHOA_6 HP Validated siRNA efficiently downregulated the 
expression of Rho A in ACHNPD cells. Treatment of the cells with the same siRNA inhibited 
stress fiber formation and chemokinesis (Fig. 4C and D). Treatment of the cells with 
Hs_RHOA_7 HP Validated siRNA showed similar results (data not shown). We also examined 
the effect of Y27632, a Rho kinase inhibitor, on morphological change in ACHNPD cells. As 
shown in Fig. 5A, Y27632 reverted the elongated morphology. Treatment of these cells with 
Y27632 also inhibited stress fiber formation and chemokinesis (Fig. 5B and C). These results 
suggest that elevated Rho A-Rho kinase signaling may be responsible for the EMT-like 
phenotype and increased motility of ACHNPD cells.  
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Discussion 
 
Since ERK is involved in a variety of tumor cell responses, inhibition of ERK was expected as 
a potential strategy in the treatment of advanced cancer. Inhibition of MEK 1 and 2, upstream 
signaling molecules of ERK, specifically and efficiently inhibits ERK activity. Thus, a number 
of small molecular weight synthetic inhibitors have been tested their activities against tumor 
cell responses in vitro and tumor progression in vivo. Among them, CI-1040, was found to 
inhibit ERK activity both in vitro and in vivo, and was well tolerated, although it provided little 
benefits for patients with advanced cancers [6, 7]. Therefore, resistance of tumor cells to 
long-term ERK inhibition allowed tumor cells to proliferate and survive during such therapy. It 
is also plausible that long-term ERK inhibition may induce aggressive phenotypes of tumor 
cells. In the present study, we showed for the first time that long-term exposure of human renal 
carcinoma cells to PD98059 induced an increase in stress fiber formation and cell motility. 
These responses were associated with elongated and scattered morphology, upregulation of 
vimentin, and a loss of -catenin junctional localization; changes that are observed in EMT 
[11]. We failed to observe the downregulation of the expression of E-cadherin and -catenin by 
chronic treatment with PD98059 in ACHN cells. Similar results were reported with 
transforming growth factor-(TGF-)-induced EMT in NMuMG breast epithelial cells [20]. 
However, a loss of E-cadherin junctional localization was demonstrated in response to 
TGF--treatment [20]. Similarly, a loss of -catenin junctional localization was observed in the 
present study (Fig. 2 E). We also observed the similar phenotypes including morphology, stress 
fiber formation, and enhanced motility in ACHN cells chronically treated with U0126 
(unpublished observation). Thus, long-term inhibition of ERK in human cancer may stimulate 
local invasion and metastasis of certain tumor cells.  
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In the present study, stress fiber formation and motility of another human renal 
carcinoma cells, VMRC-RCW cells, were not stimulated by the long-term treatment with 
PD98059. This treatment, however, upregulated the expression of ERK and reduced the 
sensitivity of proliferative activity to PD98059, which were observed in ACHNPD cells (Fig. 
2D and data not shown). Therefore, it seems likely that upregulation of ERK is a fundamental 
response, whereas enhanced stress fiber formation and cell motility may be a cell type-specific 
response in tumor cells chronically treated with PD98059. The mechanism underlying the lack 
of enhanced stress fiber formation and motility in VMRC-RCW cells is not clear at present. 
One possibility is that Rho A activity in these cells might be already increased before long-term 
exposure to PD98059. Nakamura et al. [13] reported that VMRC-RCW cells showed increased 
PI3-kinase activity by overexpression of hepatocyte growth factor receptor and subsequent 
ligand-independent activation of its tyrosine kinase activity. Motility of VMRC-RCW cells 
was inhibited by LY294002 [13]. Thus, the status of PI3-kinase activity may reflect stress fiber 
formation and motility of tumor cells following long-term treatment with PD98059.  
The motility of tumor cells is positively regulated by several other signaling molecules, 
such as Src family kinases, phosphoinositide 3-kinase (PI3-kinase), and ERK [3, 21, 22]. 
However, Src inhibitor, PP2, or PI3-kinase inhibitor, LY294002, failed to inhibit stress fiber 
formation and chemokinesis by ACHNPD cells (data not shown). We reported previously that 
overexpression of ERK 2 was associated with reduced proliferation sensitivity to PD98059 in 
ACHNPD cells [10]. However, downregulation of ERK 2 by specific siRNA also failed to 
inhibit stress fiber formation and chemokinesis by these cells (data not shown). In ACHNPD 
cells, Rho A activity was increased compared to its parental cells (Fig. 4A). The increased 
stress fiber formation and motility of these cells were dependent on Rho A-Rho kinase activity, 
because these cellular responses were inhibited by treatment with Rho A siRNA to 
downregulate the expression of Rho A or Rho kinase inhibitor Y27632 (Figs. 4 and 5). 
Kanda S et al., Page 14 
Extrapolation of these results to a clinical setting suggests that the combination of MEK 
inhibitors and Rho kinase inhibitors may enhance the antitumor activity of the former and be 
potentially useful in the treatment of patients with advanced cancers.  
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Figure legends 
 
Figure 1.  PD98059 at 50 M efficiently inhibits serum-induced activation of ERK in human 
renal carcinoma cells. Two human renal carcinoma cell lines, ACHN cells and VMRC-RCW 
cells, were seeded onto wells of 24-well plates and cultured for 24 h. Cells were then 
serum-starved overnight and a fresh serum-free medium was added with or without 50 M 
PD98059 and incubated for 2 h. The indicated cells were stimulated with 10% (Vo/Vo) FBS 
for the indicated periods and lysed. Proteins were separated onto SDS-PAGE, followed by 
transfer onto PVDF membranes. Activated ERK was detected with anti-phospho-MAPK 
antibody. Reproducible results were obtained from two independent experiments. 
 
Figure 2. (A) Long-term treatment of ACHN cells with 50 M PD98059 induces EMT-like 
phenotype. ACHN cells were cultured for more than 4 weeks in the presence or absence of 50 
M PD98059, denoted ACHNPD cells and ACHNpa cells, respectively. Pictures were taken by 
a phase-contrast microscope. (B) Long-term exposure to 50 M PD98059 upregulates the 
expression of vimentin and ERK 2 in ACHNPD cells. Cells were cultured in the wells of 
24-well plates and proteins were extracted from their lysates. Expression of particular proteins 
was determined by immunoblotting with the indicated antibodies. Reproducible results were 
obtained from two independent experiments. (C) Long-term exposure of VMRC-RCW cells to 
50 M PD98059 does not induce morphological changes. VMRC-RCW cells were cultured for 
more than 4 weeks in the presence or absence of 50 M PD98059, denoted VMRC-RCWPD 
cells and VMRC-RCWpa cells, respectively. Pictures were taken by a phase-contrast 
microscope. (D) Long-term treatment of VMRC-RCWPD cells with 50 M PD98059 
upregulates the expression of ERK2, but not vimentin. Cells were cultured in the well of 
24-well plates and proteins were extracted from their lysates. Expression of particular proteins 
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was determined by immunoblotting with the indicated antibodies. Reproducible results were 
obtained from two independent experiments. (E) Long-term exposure to 50 M PD98059 
induces a loss of -catenin junctional localization in ACHN cells. ACHNpa cells and ACHNPD 
cells were seeded onto coverslips and localization of -catenin was examined by indirect 
immunofluorescent staining.  
 
Figure 3. (A) Stress fiber formation in ACHNpa cells and ACHNPD cells. Cells grown on 
coverslips were serum-starved and left unstimulated or stimulated with 10% FBS. Cells were 
fixed and polymerized actin was visualized by incubation with TRITC-conjugated phalloidin. 
Reproducible results were obtained from three independent experiments. (B) Chemokinesis of 
ACHNpa cells and ACHNPD cells. Cells were suspended in MEM and NEAA with or without 
10% FBS and were seeded onto the upper surface of Transwell inserts pre-coated with type I 
collagen. The inserts were then placed in wells containing MEM and NEAA with or without 
10% FBS. Either 0.1% DMSO (ACHNpa cells) or 50 µM PD98059 (ACHNPD cells) was added 
to the culture medium in both the upper and lower wells. After 24 h, the cells were fixed, and 
those that had migrated to the lower membrane surface of Transwell inserts were stained with 
Giemza solution and counted microscopically. Data are the mean number of cells ± SD of four 
wells. Reproducible results were obtained from two independent experiments.  
 
Figure 4. (A) Rho A activity is higher in ACHNPD cells than in ACHNpa cells. The active form 
Rho A was precipitated from 90% of either ACHNpa or ACHNPD cell lysate with Rhotekin 
RBD-GST conjugated beads, separated onto SDS-PAGE and precipitated Rho A was detected 
by immunoblotting. The remaining 10% lysate was used for the examination of loaded protein 
by immunoblotting with anti-Rho A and anti-vinculin antibodies. Reproducible results were 
obtained from two independent experiments. (B) Expression of Rho A in ACHNPD cells is 
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downregulated by treatment with Rho A siRNA. Cells grown in 24-well plates were treated 
with the indicated siRNA. Two days later, the cells were lysed and proteins from 1  104 cells 
were examined for Rho A expression by immunoblotting. Immunoblotting with anti-vinculin 
antibody was performed to assess the loaded proteins. (C) Effect of Rho A siRNA on stress 
fiber formation of ACHNPD cells. Cells grown on coverslips were treated with the indicated 
siRNA. Two days later, stress fiber formation was examined as described in the legend of Fig. 
3 A. Reproducible results were obtained from two independent experiments. (D) Effect of Rho 
A siRNA on chemokinesis of ACHNPD cells. Cells grown in 6-well plates were treated with the 
indicated siRNA. Two days later, the chemokinesis assay was carried out as described in the 
legend of Fig. 3 B. Data are mean ± SD of four wells. Reproducible results were obtained in 
two independent experiments. 
 
Figure 5. (A) Effect of Y27632 on the morphology of ACHNPD cells. Cells grown in the well 
of 24-well plates were serum-starved and treated with either water (vehicle) or 10 µM Y27632 
for 2 h. Pictures were taken as described in the legend of Fig. 2 A. (B) Effect of Y27632 on 
stress fiber formation of ACHNPD cells. Cells grown on coverslips were serum-starved and 
treated with either water or 10 µM Y27632 for 2 h. Stress fiber formation was examined as 
described in the legend for Fig. 3 A. Reproducible results were obtained from two independent 
experiments. (C) Effect of Y27632 on chemokinesis of ACHNPD cells. Cells suspended in 
serum-free medium supplemented with either water or 10 µM Y27632 were seeded onto the 
upper surface of Transwell inserts, and the chemokinesis assay was performed as described in 
the legend of Fig. 3 B. Bars represent mean cell number ± SD of four wells. Reproducible 
results were obtained from two independent experiments.  
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